All News

Neoleukin Therapeutics Announces Publication in Science of De Novo Protein Decoys that Block COVID-19 Infection In Vitro and Protect Animals In Vivo

November 5, 2020 – LSBC Comms

– Intranasal administration of NL-CVX1 protects hamsters from lethal SARS-CoV-2 infection – – Designed to resist viral mutational escape by mimicking the natural target of the spike protein – SEATTLE, Nov. 05, 2020 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods… Read More

Member News

InMed Pharmaceuticals to Report First Quarter Fiscal 2021 Financial Results and Business Update on November 6, 2020

November 4, 2020 – InMed Pharmaceuticals Inc.

Vancouver, BC – November 4, 2020 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need… Read More

Member News

First Healthy Volunteer Dosed in Symvivo’s Phase 1 Clinical Trial of bacTRL-Spike™, an Oral COVID-19 Vaccine Candidate

November 2, 2020 – Symvivo Corporation

November 02, 2020 –BURNABY, British Columbia–(BUSINESS WIRE)–Symvivo Corporation, a clinical-stage biotechnology company advancing a proprietary bacTRL™ gene delivery platform, today announced the enrollment and dosing of the first healthy volunteer… Read More

Member News

Aurinia Announces Outcome of AUDREY™ Clinical Trial in Dry Eye Syndrome

November 2, 2020 – Aurinia Pharmaceuticals Inc.

-The trial did not achieve statistical significance on the primary endpoint of ≥ 10mm improvement in Schirmer Tear Test (STT) at 4 weeks – – Company to suspend development program for… Read More

Member News

Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes

November 2, 2020 – Zucara Therapeutics Inc.

ZT-01 Development for T2D to be Supported by Nearly $450K in Non-Dilutive Funding – Toronto, Canada, November 2, 2020 – Zucara Therapeutics Inc. (“Zucara” or the “Company”), a diabetes life… Read More

Neoleukin Therapeutics Announces Publication in Science of De Novo Protein Decoys that Block COVID-19 Infection In Vitro and Protect Animals In Vivo

InMed Pharmaceuticals to Report First Quarter Fiscal 2021 Financial Results and Business Update on November 6, 2020

First Healthy Volunteer Dosed in Symvivo’s Phase 1 Clinical Trial of bacTRL-Spike™, an Oral COVID-19 Vaccine Candidate

Aurinia Announces Outcome of AUDREY™ Clinical Trial in Dry Eye Syndrome

Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes

Category:

Sector:

Archives:

Neoleukin Therapeutics Announces Publication in Science of De Novo Protein Decoys that Block COVID-19 Infection In Vitro and Protect Animals In Vivo

InMed Pharmaceuticals to Report First Quarter Fiscal 2021 Financial Results and Business Update on November 6, 2020

First Healthy Volunteer Dosed in Symvivo’s Phase 1 Clinical Trial of bacTRL-Spike™, an Oral COVID-19 Vaccine Candidate

Aurinia Announces Outcome of AUDREY™ Clinical Trial in Dry Eye Syndrome

Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes

Newsletter Signup